Klik HIER voor de richtlijn 'Diagnostiek multipel myeloom' van de HOVON Myeloom werkgroep. 

Klik HIER voor de richtlijn 'Multipel myeloom' van de HOVON Myeloom werkgroep. 


  1. Moreau P. et al. ESMO Clinical practice guidelines for diagnosis, treatment and follow up. Annals of Oncology 2017; 28: supplement 4
  2. Delforge M. and Ludwig H. How I manage the toxicities of myeloma drugs. Blood 2017; 129:2359-2367
  3. Rajkumar S. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncology 2014; 15: e538-48
  4. Palumbo A. et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood 2015; 125: 2068-2074
  5. Cowan A. et al. Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study. Lancet Haematol 2023; 10:e203-12
  6. Sonneveld P. et al. Daratumumab, bortezomib, lenalidomide and dexamethasone for multiple myeloma. NEJM 2023; DOI: 10.1056/NEJMoa2312054


Ga terug naar de MM homepage of lees meer over MM:

Ga terug naar de algemene homepage Behandelprotocollen.